



ADULT MEDICATION GUIDELINE

Ipratropium

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Anticholinergic

Presentation

Metered Dose Inhaler: 21 microg/actuation

Nebule: 500 microg/mL

Storage

Store at room temperature, below 25°C. Protect from light.

Dose

COPD or asthma

Inhaled MDI:

2 to 4 inhalations (42-84 micrograms) 3 to 4 times daily when required.

Nebulised:

250-500 micrograms up to 3 or 4 times daily.

Severe acute asthma**Inhaled MDI:**

8 inhalations (168 micrograms) every 20 minutes for 3 doses, with salbutamol.

Nebulised:

500 micrograms every 20 minutes for 3 doses, with salbutamol.

Administration**Inhalation**

Prime the inhaler twice before the first use or if the inhaler has not been used for more than 3 days. Inhale ONE puff by mouth at a time. Use spacer if required. Speak to your pharmacist for further details.

Nebulisation

Dilute solution for nebulisation to 2-3mL with sodium chloride 0.9%.

Do not allow spray from inhaler or nebuliser to come into contact with eyes.

Monitoring

Monitor for eye pain or discomfort, blurred vision or visual halos, or difficulty urinating.

Pregnancy

1st Trimester: Considered safe to use

2nd Trimester: Considered safe to use

3rd Trimester: Considered safe to use

Breastfeeding

Considered safe to use

Related Policies, Procedures & Guidelines

WNHS Pharmaceutical and Medicines Management Guidelines:

[Medication Administration](#)

[Pre-operative Medication Management](#)

References

Australian Medicines Handbook. Ipratropium. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2023 [cited 2023 Apr 27]. Available from: <https://amhonline.amh.net.au/>









MIMS Australia. Atrovent Nebulising Solution. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2020 [cited 2023 May 08]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. Atrovent Metered Aerosol (CFC-free). In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2022 [cited 2023 May 10]. Available from: <https://www.mimsonline.com.au>

AusDI. Atrovent (ipratropium bromide monohydrate) inhalation solution [Internet]. AusDI By MedicalDirector; 2024 [cited 2024 Aug 06]. Available from: <https://ausdi-hcn-com-au.kelibresources.health.wa.gov.au/productInformation.hcn?file=p01414>

AusDI. Atrovent (ipratropium bromide monohydrate) pressurised inhalation aerosol [Internet]. AusDI By MedicalDirector; 2024 [cited 2024 Aug 06]. Available from: <https://ausdi-hcn-com-au.kelibresources.health.wa.gov.au/productInformation.hcn?file=p01412>

The Royal Women's Hospital. Ipratropium. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2023 May 10]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Ipratropium, Atrovent, COPD, asthma, nebulisation, bronchospasm				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	June 2015	Last Reviewed:	April 2020	Review Date:	10/05/2023
Endorsed by:	Medicines and Therapeutics Committee			Date:	06/08/2024
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2024

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.